Coronary Stents - Medical Devices Pipeline Assessment, 2020

2.1 Coronary Stents Overview

3.1 Coronary Stents-Pipeline Products by Stage of Development
3.2 Coronary Stents-Pipeline Products by Segment
3.3 Coronary Stents-Pipeline Products by Territory
3.4 Coronary Stents-Pipeline Products by Regulatory Path
3.5 Coronary Stents-Pipeline Products by Estimated Approval Date
3.6 Coronary Stents-Ongoing Clinical Trials

4.1 Coronary Stents Companies-Pipeline Products by Stage of Development
4.2 Coronary Stents-Pipeline Products by Stage of Development

Table 1: Coronary Stents-Pipeline Products by Stage of Development
Table 2: Coronary Stents-Pipeline Products by Segment
Table 3: Coronary Stents-Pipeline Products by Territory
Table 4: Coronary Stents-Pipeline Products by Regulatory Path
Table 5: Coronary Stents-Pipeline Products by Estimated Approval Date
Table 6: Coronary Stents-Ongoing Clinical Trials
Table 7: Coronary Stents Companies-Pipeline Products by Stage of Development
Table 8: Coronary Stents-Pipeline Products by Stage of Development
Table 9: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Second Generation Bioresorbable Vascular Scaffold-Product Status
Table 11: Second Generation Bioresorbable Vascular Scaffold-Product Description
Table 12: Xience SBA Everolimus Eluting Coronary Stent System-Product Status
Table 13: Xience SBA Everolimus Eluting Coronary Stent System-Product Description
Table 14: XIENCE Thin man DES-Product Status
Table 15: XIENCE Thin man DES-Product Description
Table 16: ZoMaxx Drug Eluting Coronary Stent System-Product Status
Table 17: ZoMaxx Drug Eluting Coronary Stent System-Product Description
Table 18: Abbott Vascular Inc-Ongoing Clinical Trials Overview
Table 19: Xience SBA Everolimus Eluting Coronary Stent System-A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 20: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 21: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 22: Xience SBA Everolimus Eluting Coronary Stent System-Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 23: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Dual Drug Eluting Stent-Product Status
Table 25: Dual Drug Eluting Stent-Product Description
Table 26: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Stenting System-Bare Metal Stent-Product Status
Table 28: Stenting System-Bare Metal Stent-Product Description
Table 29: Stenting System-Drug Eluting Stent-Product Status
Table 30: Stenting System-Drug Eluting Stent-Product Description
Table 31: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Drug Eluting Stent-Product Status
Table 33: Drug Eluting Stent-Product Description
Table 34: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 35: BMS-Avantgarde-Product Status
Table 36: BMS-Avantgarde-Product Description
Table 37: Commander-Product Status
Table 38: Commander-Product Description
Table 39: Cre8 DES-Product Status
Table 40: Cre8 DES-Product Description

Figure 1: Coronary Stents-Pipeline Products by Stage of Development
Figure 2: Coronary Stents-Pipeline Products by Segment
Figure 3: Coronary Stents-Pipeline Products by Territory
Figure 4: Coronary Stents-Pipeline Products by Regulatory Path
Figure 5: Coronary Stents-Pipeline Products by Estimated Approval Date
Figure 6: Coronary Stents-Ongoing Clinical Trials